[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2820322B1 - Formulation pharmaceutique de propionate de fluticasone - Google Patents

Formulation pharmaceutique de propionate de fluticasone

Info

Publication number
FR2820322B1
FR2820322B1 FR0202756A FR0202756A FR2820322B1 FR 2820322 B1 FR2820322 B1 FR 2820322B1 FR 0202756 A FR0202756 A FR 0202756A FR 0202756 A FR0202756 A FR 0202756A FR 2820322 B1 FR2820322 B1 FR 2820322B1
Authority
FR
France
Prior art keywords
fluticasone propionate
pharmaceutical formulation
formulation
hydrofluoroalkane
hfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0202756A
Other languages
English (en)
Other versions
FR2820322A1 (fr
Inventor
Alan Leslie Cripps
Paul Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27255761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2820322(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9921396.9A external-priority patent/GB9921396D0/en
Priority claimed from GB0014451A external-priority patent/GB0014451D0/en
Priority claimed from GB0018654A external-priority patent/GB0018654D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of FR2820322A1 publication Critical patent/FR2820322A1/fr
Application granted granted Critical
Publication of FR2820322B1 publication Critical patent/FR2820322B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
FR0202756A 1999-09-11 2002-03-05 Formulation pharmaceutique de propionate de fluticasone Expired - Fee Related FR2820322B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9921396.9A GB9921396D0 (en) 1999-09-11 1999-09-11 Pharmaceutical formulation
GB0014451A GB0014451D0 (en) 2000-06-13 2000-06-13 Pharmaceutical formulation
GB0018654A GB0018654D0 (en) 2000-07-28 2000-07-28 Pharmaceutical formulation

Publications (2)

Publication Number Publication Date
FR2820322A1 FR2820322A1 (fr) 2002-08-09
FR2820322B1 true FR2820322B1 (fr) 2005-03-11

Family

ID=27255761

Family Applications (4)

Application Number Title Priority Date Filing Date
FR0011547A Expired - Fee Related FR2798290B1 (fr) 1999-09-11 2000-09-11 Formulation pharmaceutique de propionate de fluticasone
FR0202756A Expired - Fee Related FR2820322B1 (fr) 1999-09-11 2002-03-05 Formulation pharmaceutique de propionate de fluticasone
FR0309598A Expired - Fee Related FR2843882B1 (fr) 1999-09-11 2003-08-04 Formulation pharmaceutique de propionate de fluticasone
FR0400541A Expired - Fee Related FR2848453B1 (fr) 1999-09-11 2004-01-21 Formulation pharmaceutique de propionate de fluticasone

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0011547A Expired - Fee Related FR2798290B1 (fr) 1999-09-11 2000-09-11 Formulation pharmaceutique de propionate de fluticasone

Family Applications After (2)

Application Number Title Priority Date Filing Date
FR0309598A Expired - Fee Related FR2843882B1 (fr) 1999-09-11 2003-08-04 Formulation pharmaceutique de propionate de fluticasone
FR0400541A Expired - Fee Related FR2848453B1 (fr) 1999-09-11 2004-01-21 Formulation pharmaceutique de propionate de fluticasone

Country Status (12)

Country Link
US (4) US6479035B1 (fr)
EP (1) EP1143930B8 (fr)
JP (1) JP2003509359A (fr)
AT (1) ATE343374T1 (fr)
AU (1) AU7026800A (fr)
CA (1) CA2317999C (fr)
DE (1) DE60031504T2 (fr)
ES (1) ES2274803T3 (fr)
FR (4) FR2798290B1 (fr)
GB (1) GB2354007B (fr)
IT (1) IT1317904B1 (fr)
WO (1) WO2001019342A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9814717D0 (en) * 1998-02-23 1998-09-02 Bespak Plc Improvements in drug delivery devices
WO2001019342A2 (fr) * 1999-09-11 2001-03-22 Glaxo Group Limited Preparation pharmaceutique renfermant du propionate de fluticasone
ATE291898T1 (de) * 1999-12-24 2005-04-15 Glaxo Group Ltd Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
EP1321159A1 (fr) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Dispositif d'actionnement pour inhalateur doseur pressurisé avec orifices percés par laser
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1340492A1 (fr) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Formulations d'aérosol pour l'administration par voie pulmonaire de medicaments avec effet systémique
MEP30108A (en) * 2002-03-01 2010-06-10 Chiesi Farmaceutici S P Formoterol superfine formulation
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
WO2007064932A2 (fr) * 2005-12-02 2007-06-07 Bayer Healthcare Llc. Dérivés de pyrrolotriazine utiles pour traiter le cancer par inhibition de la kinase aurora
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
EA031157B9 (ru) 2009-10-01 2019-01-31 Адэр Фармасьютикалз, Инк. Вводимая перорально кортикостероидная композиция
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
CN102379846B (zh) * 2011-10-21 2014-07-02 江苏长风药业有限公司 以氢氟烷烃和聚乙二醇为辅料氟替卡松丙酸酯气雾剂制剂
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
ES2813397T3 (es) 2012-05-08 2021-03-23 Nicox Ophthalmics Inc Forma polimórfica de propionato de fluticasona
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
WO2015034678A2 (fr) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticostéroïde contenant des compositions de comprimés se désintégrant par voie orale pour œsophagite à éonisophiles
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
EP3797964B1 (fr) 2019-09-26 2023-06-07 Presspart Manufacturing S.A. Outil de moulage par injection pour inhalateur de dose mesurée
US20230271770A1 (en) * 2020-04-21 2023-08-31 Amphastar Pharmaceuticals, Inc. Anti-Viral Pharmaceutical Formulations Administered Via Devices for Lung Targeted Delivery

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL289785A (fr) * 1962-11-29
CH634480A5 (de) * 1977-11-25 1983-02-15 Schwarzkopf Gmbh Hans Unter druck stehendes aerosolpraeparat.
DE2949933A1 (de) 1979-12-12 1981-06-19 Wabco Fahrzeugbremsen Gmbh, 3000 Hannover Vorrichtung zum verhindern von schlingerbewegungen eines anhaengers
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
GB2235627B (en) 1989-09-08 1993-09-01 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5919827A (en) 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
WO1992006675A1 (fr) 1990-10-18 1992-04-30 Minnesota Mining And Manufacturing Company Formulation d'aerosol contenant du beclomethasone 17,21 dipropionate
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
WO1993011745A1 (fr) 1991-12-12 1993-06-24 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5653962A (en) 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
GB2288978B (en) 1992-12-09 1997-04-09 Boehringer Ingelheim Pharma Hydrocarbon inhalant solutions stabilised by organic or inorganic acids
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
PT1166811E (pt) 1995-04-14 2007-02-28 Smithkline Beecham Corp Inalador doseador para propionato de fluticasona
DE69734017T2 (de) 1996-12-04 2006-06-14 Link Products Ltd Arzneimittelzusammensetzungen und vorrichtungen zu deren verabreichung
US6461591B1 (en) * 1997-02-05 2002-10-08 Jago Research Ag Medical aerosol formulations
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
DE69909771T2 (de) 1998-04-30 2004-04-15 3M Innovative Properties Co., Saint Paul Dosierventil für pharmazeutisches aerosol
ATE253896T1 (de) 1998-06-18 2003-11-15 Boehringer Ingelheim Pharma Zwei oder mehrere wirkstoffe enthaltende pharmazeutische aerosolformulierungen
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
ATE283033T1 (de) 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
IT1303788B1 (it) 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US6231519B1 (en) * 1999-05-04 2001-05-15 Nokia Corporation Method and apparatus for providing air quality analysis based on human reactions and clustering methods
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
WO2001019342A2 (fr) * 1999-09-11 2001-03-22 Glaxo Group Limited Preparation pharmaceutique renfermant du propionate de fluticasone
ES2234694T3 (es) 1999-11-23 2005-07-01 Glaxo Group Limited Formulaciones farmaceuticas de salmeterol.
GB0002798D0 (en) 2000-02-09 2000-03-29 Glaxo Group Ltd Actuator nozzle for metered dose inhaler

Also Published As

Publication number Publication date
EP1143930A3 (fr) 2002-09-11
DE60031504T2 (de) 2007-04-05
US6479035B1 (en) 2002-11-12
GB2354007B (en) 2003-10-22
ATE343374T1 (de) 2006-11-15
CA2317999A1 (fr) 2001-03-11
CA2317999C (fr) 2004-11-09
FR2848453B1 (fr) 2010-09-03
FR2848453A1 (fr) 2004-06-18
US6630129B2 (en) 2003-10-07
IT1317904B1 (it) 2003-07-15
FR2798290A1 (fr) 2001-03-16
DE60031504D1 (de) 2006-12-07
FR2798290B1 (fr) 2003-09-12
WO2001019342A3 (fr) 2001-08-09
AU7026800A (en) 2001-04-17
US20040037783A1 (en) 2004-02-26
US20030086876A1 (en) 2003-05-08
EP1143930B8 (fr) 2008-03-19
ES2274803T3 (es) 2007-06-01
US7220403B2 (en) 2007-05-22
EP1143930A2 (fr) 2001-10-17
FR2843882B1 (fr) 2011-04-22
ITRM20000491A0 (it) 2000-09-11
JP2003509359A (ja) 2003-03-11
FR2843882A1 (fr) 2004-03-05
EP1143930B1 (fr) 2006-10-25
FR2820322A1 (fr) 2002-08-09
GB0022222D0 (en) 2000-10-25
GB2354007A (en) 2001-03-14
ITRM20000491A1 (it) 2002-03-11
WO2001019342A2 (fr) 2001-03-22
US20040157815A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
FR2848453B1 (fr) Formulation pharmaceutique de propionate de fluticasone
AU2206801A (en) Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
US6136294C1 (en) Amino acid stabilized medical aerosol formulation
PT1037604E (pt) Composicoes farmaceuticas de aerossol
DE60308997D1 (de) Formulierungen zur inhalation
MXPA03000442A (es) Una formulacion medicinal en aerosol.
DK0918507T3 (da) Aerosolformuleringer
HK1042444A1 (zh) 藥用噴霧製劑
GB0016876D0 (en) Novel formulation
AU1534501A (en) Pharmaceutical formulations of salmeterol
CA2446562A1 (fr) Formulation pharmaceutique de propionate de fluticasone
MX9707238A (es) Formulaciones en aerosol de butixocort.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20130531